overview | clodronate disodium is an organic compound, developed by Leiras pharmaceutical factory in the Netherlands and listed in 1986. it mainly inhibits bone resorption, prevents hydroxyapatite dissolution and inhibits osteoclast activity. |
use | clodronate disodium (tetrahydrate) can treat bone metastases and relieve pain, and has the best analgesic effect on bone metastases of breast cancer, with an effective rate of 90%. |
biological activity | Clodronate disodium tetrahydrate (Disodium clodronate tetrahydrate) is the first generation bisphosphonate, which has anti-osteoporosis, anti-inflammatory and analgesic effects. Clodronate disodium tetrahydrate is a selective, efficient, reversible, Cl-competitive vesicular nucleotide transporter (VNUT) blocker with an IC50 value of 15.6 nM. Clodronate disodium tetrahydrate can inhibit neuronal release of vesicular ATP and relieve chronic neuropathic pain and inflammatory pain. |
target | vesicular ATP release |
Animal Model:
| C57BL/6 mice (22-30 g) |
Dosage:
| 10 mg/kg |
Administration:
| Intravenous injection |
Result:
| Attenuated carrageenan- or complete Freund’s adjuvant (CFA)-evoked inflammatory pain. |